# The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System

Study · id `cardio:ct-nct04559945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04559945](<https://clinicaltrials.gov/study/NCT04559945>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04559945

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1276 participants.

## Technical summary

Registry record NCT04559945. Allocation not applicable; no masking; primary purpose treatment. Start 2020-11-13 (actual); primary completion 2022-07-18 (actual). Results posted on 2026-05-20.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1276 participants (enrolled count; ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Started: 2020-11-13 (actual) (ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Primary completion: 2022-07-18 (actual) (ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Completion: 2023-09-15 (actual) (ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Results first posted: 2026-05-20 (ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; France; Italy; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT04559945, source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04559945-2026-05-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: The LEADLESS II IDE Study for the Aveir VR Leadless Pacemaker System
- Condition: Cardiac Rhythm Disorder
- Condition: Bradycardia
- Intervention (Device): Aveir VR Leadless Pacemaker System
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Bradycardia (`cardio:bradycardia`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: d15d5b4898d3af257a69246e37e5bce0504a53cc4080df9bc12f1a7f3fd97a5e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
